Canada-based robotic mobility technology company Human in Motion Robotics has secured Health Canada approval to market and sell the XoMotion exoskeleton in Canada.
According to the company, XoMotion is the world’s most advanced exoskeleton and is set to transform ambulatory training in rehabilitation facilities.
XoMotion is designed with self-balancing and hands-free functionality to support patients with spinal cord injuries (SCI), stroke, and other neurological conditions.
The exoskeleton comes with the ability to mimic natural, human-like movements, which makes it intuitive and easy to use for both patients and therapists.
It also reduces the physical burden on therapists by lifting, assisting, mobilising, and training patients, enhancing the safety and efficiency of rehabilitation programmes, said the company.
Human in Motion Robotics CEO Siamak Arzanpour said: “With XoMotion, we are setting a new standard in rehabilitation technology.
“Our exoskeleton not only empowers patients by facilitating natural and functional movement but also supports therapists by reducing the physical demands of their work.
“Gaining regulatory approval from Health Canada is a crucial step towards our goal of global accessibility, and we are committed to continuing this progress in other key markets.”
XoMotion’s self-balancing feature offers stability and safety during use, and hands-free feature enables natural movement and normal upper body function.
The exoskeleton can perform a wide range of complex ambulatory tasks, is suitable for various conditions, and is safe for patients from acute to chronic stages of injury, said the company.
Human in Motion Robotics recently secured its Medical Devices Establishment License to commercialise XoMotion in Canada, a significant step towards expanding its reach.
With the regulatory approval, XoMotion became the first self-balancing exoskeleton system available for acquisition in Canada, the company said.
Furthermore, Human in Motion Robotics aims to obtain regulatory approvals in other important global markets, including the US, Asia, and the EU.
